FGF23 ELISA KITS

BIOMEDICA



FGF23 (intact)
FGF23 (C-terminal)

Fully validated

For serum and plasma

Setting the **standard**
for clinical research.

FGF23 intact ELISA (Cat.No. BI-20700)

ELISA for the quantitative determination of human FGF23 (intact)

Features and Benefits

- RELIABLE – fully validated for plasma according to ICH Q2 guidelines
- FAST ONE-STEP ELISA – only 3.5 h total incubation time
- BIOLOGICALLY RELIABLE DATA – plasma based standards & controls
- HIGH SPECIFICITY and SENSITIVITY – characterized antibodies
- COMPARABLE RESULTS – correlates with existing methods

Assay Characteristics

- Method: Sandwich ELISA, 12x8 well-strips
- Sample type: Plasma (EDTA, heparin, citrate), serum, urine, cell culture *
- Sample volume: 50 µl / well
- Incubation: 2 h / 1 h / 30 min
- Standard range: 0 – 1600 pg/ml
- Sensitivity: 5.4 pg/ml (= 0.21 pmol/l)
- Conversion factor: 1 pmol/l = 26 pg/ml (MW: 26 kDa)
- Specificity: Endogenous and recombinant human intact FGF23
- Precision: In-between-run (n=9): ≤ 6% CV, within-run (n=3): ≤ 8% CV

Typical Standard Curve



FGF23 (intact) Levels in Serum and Plasma

n=22	Median intact FGF23 [pg/ml]
EDTA plasma	24.9
Heparin plasma	26.4
Citrate plasma	17.4
Serum	14.8



High correlation of FGF23 (intact) values between serum and plasma samples

Intact FGF23 (iFGF23) levels measured in serum and plasma samples from chronic kidney disease (CKD) patients (n=16) are highly correlated (R= 0.9835).

Accuracy

Matrix	n	Mean S/R [%]	
		+160 pg/ml	+800 pg/ml
Serum	6	70	91
EDTA plasma	6	94	100
Heparin plasma	1	82	79
Citrate plasma	1	97	103

Parallelism

Matrix	n	R of dilution steps [%]		
		1+1	1+3	1+7
Serum	6	87	74	67
EDTA plasma	5	107	108	111
Heparin plasma	1	99	97	107
Citrate plasma	1	143	137	130

*This ELISA is optimized and validated for human plasma samples. Serum, urine and cell culture supernatant are compatible with this ELISA.
More information and full validation report are available at www.bmgrp.com

Divischgasse 4 · 1210 Vienna · Austria · T +43 1 291 07 45 · F +43 1 291 07 6389 · info@bmgrp.com · www.bmgrp.com

FGF23 (C-terminal) multi-matrix ELISA (Cat.No. BI-20702)

ELISA for the quantitative determination of human FGF23 (C-terminal)

Features and Benefits

- RELIABLE – fully validated for plasma and serum according to ICH Q2 guidelines
- HIGHLY SENSITIVE – clear differentiation even at low serum FGF23 levels
- BIOLOGICALLY RELIABLE DATA – serum based standards & controls
- HIGH SPECIFICITY – characterized antibodies
- COMPARABLE RESULTS – correlates with existing methods

Assay Characteristics

- Method: Sandwich ELISA, 12x8 well-strips
- Sample type: Plasma (EDTA, heparin, citrate), serum, urine, cell culture *
- Sample volume: 50 µl / well
- Incubation: 20-24 h / 1 h / 30 min
- Standard range: 0 – 20 pmol/l (= 150.4 pg/ml)
- Sensitivity: 0.08 pmol/l (= 0.6 pg/ml)
- Conversion factor: 1 pmol/l = 7.52 pg/ml (MW: 7.52 kDa)
- Specificity: Human FGF23 (intact and C-terminal fragments of endogenous and recombinant human FGF23)
- Precision: In-between (n=10): ≤ 10% CV; within-run (n=6): ≤ 12% CV

Typical Standard Curve



FGF23 (C-terminal) Levels in Serum and Plasma



Accuracy

Matrix	n	Mean S/R [%]	
		+5 pmol/l	+10 pmol/l
Serum	13	96	89
EDTA plasma	7	97	94
Heparin plasma	8	101	92
Citrate plasma	7	100	90

Parallelism

Matrix	n	R of dilution steps [%]		
		1+1	1+3	1+7
Serum	9	105	100	108
EDTA plasma	4	103	103	106
Heparin plasma	10	102	106	104
Citrate plasma	5	102	106	101

Specificity

The assay measures both intact FGF23 and C-terminal fragments of FGF23.
The FGF23 detected in this assay is stable after sample collection. The assay can be used for all sample types.

Related Biomedica Products

- Sclerostin ELISA, Cat.No. BI-20492
- DKK-1 ELISA, Cat.No. BI-20413
- FREE soluble RANKL ELISA, Cat.No. BI-20462
- Osteoprotegerin ELISA, Cat.No. BI-20403

*This ELISA is optimized and validated for human plasma and serum samples. Urine and cell culture supernatant are compatible with this ELISA. More information and full validation report are available at www.bmgrp.com

Divischgasse 4 · 1210 Vienna · Austria · T +43 1 291 07 45 · F +43 1 291 07 6389 · info@bmgrp.com · www.bmgrp.com

Setting the **standard** for **clinical** research.

www.bmgrp.com

BIOMEDICA
IMMUNOASSAYS
Divischgasse 4 · 1210 Vienna · Austria
T +43 1 291 07 45 · F +43 1 291 07 6389
info@bmgrp.com · www.bmgrp.com

FGF23-092024